PHM Stock Analysis: Pharma Mar S.A. | MC
Biotechnology | MC, Spain | Market Cap: 1.454m EUR | 12M Return: 4.2% | ES0169501022 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.10M
Qual. Beats: 0
Rev. Trend: 87.3%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Pharma Mar, S.A. (PHM) is a Madrid-based biopharmaceutical company founded in 1986 that focuses on discovering, developing, and commercializing bio-active compounds for oncology. It operates through two segments: Oncology and RNA Interference (gene-silencing therapeutics), with commercial activity spanning Europe, the United States, and other international markets.
The companys marketed portfolio includes Yondelis (derived from the sea squirt Ecteinascidia turbinata, approved for soft tissue sarcoma and ovarian cancer), Zepzelca (a synthetic agent for small cell lung cancer), and Aplidin (extracted from the ascidian Aplidium albicans, indicated for multiple myeloma). Pharma Mars development pipeline includes LAGOON and SaLuDo in Phase III trials, PM534 and PM54 in Phase I for solid tumors, and SYL1801 in Phase II for ophthalmologic conditions such as age-related macular degeneration.
As a small-cap biotechnology firm, Pharma Mar follows a high-risk, R&D-intensive business model typical of the biopharma sector, where revenue depends on a limited number of approved oncology products and long product development cycles subject to regulatory approval. The company is also notable for its specialization in marine-derived pharmaceuticals, a niche area of natural-product drug discovery, and complements its oncology work with RNA interference-based research aimed at silencing disease-related gene expression.
- Zepzelca US sales growth drives oncology revenue
- LAGOON Phase III readout in small cell lung cancer
- Yondelis faces competition in soft tissue sarcoma market
| Net Income: 56.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 12.62 > 1.0 |
| NWC/Revenue: 83.48% < 20% (prev 85.39%; Δ -1.91% < -1%) |
| CFO/TA 0.16 > 3% & CFO 62.2m > Net Income 56.1m |
| Net Debt (-120.2m) to EBITDA (43.1m): -2.79 < 3 |
| Current Ratio: 2.85 > 1.5 & < 3 |
| Outstanding Shares: last quarter (17.3m) vs 12m ago -1.36% < -2% |
| Gross Margin: 90.57% > 18% (prev 94.98%; Δ -4.41% > 0.5%) |
| Asset Turnover: 58.95% > 50% (prev 54.35%; Δ 4.60% > 0%) |
| Interest Coverage Ratio: 14.17 > 6 (EBIT TTM 34.9m / Interest Expense TTM 2.46m) |
| A: 0.46 (Total Current Assets 280.9m - Total Current Liabilities 98.4m) / Total Assets 393.6m |
| B: 0.61 (Retained Earnings 239.8m / Total Assets 393.6m) |
| C: 0.09 (EBIT TTM 34.9m / Avg Total Assets 370.9m) |
| D: 1.76 (Book Value of Equity 250.8m / Total Liabilities 142.8m) |
| Altman-Z'' = 7.50 = AAA |
| DSRI: 0.84 (Receivables 57.9m/59.8m, Revenue 218.6m/189.3m) |
| GMI: 1.05 (GM 94.98% / 90.57%) |
| AQI: 1.13 (AQ_t 0.13 / AQ_t-1 0.12) |
| SGI: 1.16 (Revenue 218.6m / 189.3m) |
| TATA: -0.02 (NI 56.1m - CFO 62.2m) / TA 393.6m) |
| Beneish M = -2.93 (Cap -4..+1) = A |
As of August 22, 2026, the stock is trading at EUR 83.30 with a total of 45,400 shares traded. Over the past week, the price has changed by -0.77%, over one month by +9.25%, over three months by -15.68% and over the past year by +4.16%.
Current recommended Stop Loss: 80.00 (which is 4% or 1.3 ATR below the current price).
Pharma Mar S.A. has no consensus analysts rating.
P/E Trailing = 26.0714
P/E Forward = 54.0541
P/S = 6.6516
P/B = 5.5887
P/EG = 0.3119
Revenue TTM = 218.6m EUR
EBIT TTM = 34.9m EUR
EBITDA TTM = 43.1m EUR
Long Term Debt = 32.1m EUR (from longTermDebt, last quarter)
Short Term Debt = 12.3m EUR (from shortTermDebt, last quarter)
Debt = 48.6m EUR (from shortLongTermDebtTotal, last quarter) + Leases 2.79m
Net Debt = -120.2m EUR (calculated: Debt 48.6m - CCE 168.9m)
Enterprise Value = 1.33b EUR (1.45b + Debt 48.6m - CCE 168.9m)
Interest Coverage Ratio = 14.17 (Ebit TTM 34.9m / Interest Expense TTM 2.46m)
EV/FCF = 26.11x (Enterprise Value 1.33b / FCF TTM 51.1m)
FCF Yield = 3.83% (FCF TTM 51.1m / Enterprise Value 1.33b)
FCF Margin = 23.37% (FCF TTM 51.1m / Revenue TTM 218.6m)
Net Margin = 25.67% (Net Income TTM 56.1m / Revenue TTM 218.6m)
Gross Margin = 90.57% ((Revenue TTM 218.6m - Cost of Revenue TTM 20.6m) / Revenue TTM)
Gross Margin QoQ = 86.21% (prev 91.47%)
Tobins Q-Ratio = 3.39 (Enterprise Value 1.33b / Total Assets 393.6m)
Interest Expense / Debt = 5.06% (Interest Expense 2.46m / Debt 48.6m)
Taxrate = 25.0% (non-US conservative default 25%)
NOPAT = 26.1m (EBIT 34.9m * (1 - 25.00%))
Current Ratio = 2.85 (Total Current Assets 280.9m / Total Current Liabilities 98.4m)
Debt / Equity = 0.19 (Debt 48.6m / totalStockholderEquity, last quarter 250.8m)
Debt / EBITDA = -2.79 (Net Debt -120.2m / EBITDA 43.1m)
Debt / FCF = -2.35 (Net Debt -120.2m / FCF TTM 51.1m)
Total Stockholder Equity = 237.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 15.13% (Net Income 56.1m / Total Assets 393.6m)
RoE = 23.64% (Net Income TTM 56.1m / Total Stockholder Equity 237.4m)
RoCE = 12.93% (EBIT 34.9m / Capital Employed (Equity 237.4m + L.T.Debt 32.1m))
RoIC = 8.82% (NOPAT 26.1m / Invested Capital 296.5m)
WACC = 6.76% (E(1.45b)/V(1.50b) * Re(6.86%) + D(48.6m)/V(1.50b) * Rd(5.06%) * (1-Tc(0.25)))
Discount Rate = 6.86% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -73.76 | Cagr: -0.44%
[DCF] Terminal Value 77.97% ; FCFF base≈31.2m ; Y1≈35.7m ; Y5≈52.6m
[DCF] Fair Price = 52.63 (EV 791.5m - Net Debt -120.2m = Equity 911.7m / Shares 17.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.36 | # QB: 0
Revenue Correlation: 87.26 | Revenue CAGR: 13.35% | SUE: 0.58 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.06 | Chg30d=-70.37% | Revisions=-25% | Analysts=4
EPS current Year (2026-12-31): EPS=2.00 | Chg30d=-13.58% | Revisions=+0% | GrowthEPS=-53.4% | GrowthRev=-4.7%
EPS next Year (2027-12-31): EPS=6.26 | Chg30d=+1.66% | Revisions=-25% | GrowthEPS=+212.5% | GrowthRev=+44.8%
[Analyst] Revisions Ratio: -40% (up=0, down=2)